Emyria Ltd (ASX:EMD) has received strong interest from potential participants for an Emryia-led study into irritable bowel syndrome (IBS).
IBS affects around 11% of the population globally and is a significant unmet need often associated with greater levels of anxiety and lower quality of life measures.
Emyria decided to launch the study following in-depth analysis of Real World Evidence (RWE) data asset on IBS patients cared for at Emyria’s clinical subsidiary Emerald Clinics.
The CALM-GUT study will inform Emyria’s general care program for IBS patients and also Emyria’s second drug development program to be called EMD-004.
EMD-004 will complement Emyria’s recent mental health focussed drug development program - EMD-003 - which is also backed by Emyria’s RWE.
Study to inform better care for patients
Managing director Dr Michael Winlo said: “We’re pleased to see strong interest in our CALM-GUT study from patients with irritable bowel syndrome.
“IBS can be a challenging condition to manage and the strong interest demonstrates the need for safe and effective options.
“We were encouraged to initiate this study based on an analysis of our Real-World Evidence and have designed it to support our second drug development program - EMD-004.
“This study will also inform how we can better care for patients with this condition and we’re very pleased to be collaborating with Dr Chris Schneider, a consultant gastroenterologist based in Melbourne, on these projects.”
Emyria’s drug development programs encompass unique clinical evidence packages, intellectual property (IP) and strategically developed clinical trial protocols informed by Emyria’s unique RWE and observational trial results.
The development programs are intended to support the registration of specific medicines for specific health indications with the Therapeutic Goods Administration’s (TGA) Australian Register of Therapeutic Goods (ARTG).